Kringle Pharma ^None

Kringle Pharma is a biopharmaceutical company that focuses on developing pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. HGF has regenerative healing abilities for liver cells, various cells, and organs, while NK4 inhibits the invasion and metastasis of tumor cells and possesses antiangiogenic activity. The company's pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases, as well as recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma was founded in 2001 and is based in Toyonaka, Japan.